Samsung Biologics (KRX:207940) entered the antibody-drug conjugate (ADC) sector, with its new 500-liter ADC production facility in Songdo, Incheon, set to commence operations in February, The Korea Herald reported Thursday.
ADCs combine monoclonal antibodies targeting cancer cells with potent drugs to improve therapeutic precision and efficacy, the report said.
The Songdo facility is a four-story unit that features large-scale purification capabilities and streamlined quality control systems, it said.
The company has deepened its collaboration with LigaChem Biosciences (KOSDAQ:141080), signing a material transfer agreement in June 2024 and committing to more than three ADC projects in 2025, the report said.
Shares of Samsung Biologics fell more than 1% in recent trade on Friday while those of LigaChem Biosciences fell nearly 1%.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。